The new guideline also recommends faster tapering to a lower dose of glucocorticoids and a longer duration of ...

DelveInsight's 'Lupus Nephritis Pipeline Insight 2024' report provides comprehensive global coverage of pipeline lupus ...

A noninvasive urinary biomarker panel predicts lupus nephritis activity and response better than proteinuria, and, if further validated, may aid diagnosis and gauge treatment response, investigators ...

Sana Biotechnology results from the phase 1 study using SC291 for the treatment of patients with SLE are expected in 2025.

GLP-1 receptor agonist use is associated with benefits in a number of different disease and may help treat patients with lupus nephritis.

Fast Track designation is designed to expedite clinical development and regulatory review timelines Enrolling patients in the GLEAM trial for SC291 in B-cell mediated autoimmune diseases, including ...

which includes extrarenal lupus and lupus nephritis. Fast Track is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet ...

Unlock your investing potential with TipRanks Premium - Now At 40% OFF!

The U.S. Food and Drug Administration gave SC291, a CD19-directed allogeneic CAR T cell therapy developed using Sana's hypoimmune platform, fast track designation, a process designed to facilitate the ...

Shares of Aurinia Pharmaceuticals Inc. (TSE:AUP – Get Free Report) (NASDAQ:AUPH) dropped 3.5% during mid-day trading on Monday . The stock traded as low as C$16.41 and last traded at C$16.76.

Live entertainment, prizes, visit with Santa and more. Our newest virtual support group offering is centered around living with lupus nephritis. Register today to help build up this newest group and ...

Bob Valamehr, Ph.D. MBA, To Become President and CEO January 1, 2025 Scott Wolchko To Retire as President and CEO after 10 years of Leadership in Pioneering iPSC-derived Cellular Immunotherapies SAN ...